**************************************************************

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives,reported that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

StemCells, Inc. (Nasdaq:STEM) reports that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the rat. Both mice and rats are used as animal models of human disease; however certain aspects of the rat’s physiology, behavior, and metabolism are closer to the human, making rats the preferred species for drug development and studying human disease. The creation of this first rat model using rat ES cells validates intellectual property owned by StemCells, which includes the rights to patents covering both rat ES and rat induced pluripotent stem (iPS) cells as well as genetically engineered rats derived from these cells.

StemCells’ broad rat pluripotent stem cell intellectual property portfolio is based upon groundbreaking research led by prominent academic researchers at the University of Edinburgh, including Dr. Qi-Long Ying who was the first to succeed in deriving and culturing the true germline competent rat ES cells required for precise genetic engineering. In this newly published study, Dr. Qi-Long Ying and his colleagues at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California demonstrated for the first time the creation of genetically modified rats using rat ES cells that have been gene targeted via homologous recombination, a method which involves adding DNA sequences to the cells to delete (’knock-out’), add (’knock-in’) or otherwise modify genes of interest. This latest work resulted in the successful generation of knock-out rats missing the tumor suppressor gene p53 for use in studying cancer, and serves as a proof-of-principle for creating genetically engineered rats using rat ES cells.

Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. report that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo. The trial also met all of its secondary and tertiary endpoints. Frequently observed adverse events were injection site reactions, flu-like symptoms and elevations in liver transaminases, as seen in other mipomersen studies.

This double-blind, placebo-controlled phase 3 study was designed to test the efficacy and safety of adding mipomersen to stable lipid-lowering therapy. Patients were randomized 2:1 to receive a 200 mg dose of mipomersen or placebo weekly for 26 weeks. The trial included 124 adult heFH patients at 26 sites in the United States and Canada. All of the patients had pre-existing coronary artery disease and LDL-C levels greater than 100 mg/dL, and were taking a maximally tolerated dose of a statin, as well as additional lipid-lowering drugs in most cases. Prior to study enrollment, 78 percent of patients had previously experienced at least one cardiovascular event and 49 percent had more than one previous cardiovascular event.

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

**************************************************************

MusclePharm® Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, reported that the National Association of People with AIDS (NAPWA) requests the approval of MusclePharm’s Recon nutritional supplement to the New York State Medicaid list of prescription medications.

MusclePharm’s Recon Nutritional Supplement contains important amino acids, assisting in reaching the higher levels of nutrition required for people living with HIV. MusclePharm’s Recon Nutritional Supplement is easily digestible, helps the absorption of amino acids and proteins. It contains essential minerals, digestive enzymes, Glutamine and other metabolic agents that maximize recovery, protein synthesis and endurance.

“We are honored with the NAPWA’s support of therapeutic nutritional supplementation and look forward to the day when MusclePharm’s Recon is available to people living with HIV in New York State and all of those who depend on Medicaid for their therapeutic needs,” stated Brad Pyatt, MusclePharm’s Chief Executive Officer. “Our safe and scientific product formulations provide unique opportunities for us to expand MusclePharm’s distribution within the medical community. We believe this increased support continues to position MusclePharm as one of the leading developers and manufacturers of nutritional supplements.”

Nutritional Supplementation has long been utilized within the HIV community to maintain and support muscle mass and help strengthen the immune system. Whey protein has been shown thru various credible studies to aid in the growth of muscle mass. Unlike other Medicaid available proteins, MusclePharm’s Recon helps to burn fat while building muscle. This is a factor essential to people living with HIV, especially those on antiviral regimens where unwanted fat may be an issue in those who often battle muscle depletion.

The Vitamin Shoppe (NYSE:VSI) is a specialty retailer and direct marketer of nutritional products ranging from vitamins and minerals to nutritional supplements, herbs, sports nutrition formulas, homeopathic remedies, and health and beauty aids. In the United States, more than 150 million people take a dietary supplement every day. The Vitamin Shoppe is the first and only choice of people seeking to fulfill their health and wellness needs.

What began as a single store in 1977 has evolved into more than 400 locations in 37 states and an informative and easy to shop web site.

The Vitamin Shoppe offers over 20,000 items from more than 400 name brands. Consumers can choose from the most trusted names in Health & Wellness, Sports Nutrition, Weight Management, and Personal Care.

The Vitamin Shoppe is a vibrant member of the communities they serve.

At The Vitamin Shoppe, every store associate or Health Enthusiast is dedicated to helping customers find “answers for every body.” Just like the customers who have made purchases with The Vitamin Shoppe during the past 30 years, the traditional definition of healthy living continues to evolve. Information is available to consumers through unprecedented outlets including television, radio, friends, family, health practitioners, and the internet. The Vitamin Shoppe offers consumers the opportunity to take charge of their own health and wellness requirements, and supplement where necessary.

PROTEONOMIX, INC. (Pinksheets:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, applauds the actions taken by the Costa Rican Ministry of Health to crack down on unauthorized stem cell clinics. The chief of the ministry’s research council, Dr. Ileana Herrera, stated, “If (stem cell treatment’s) efficacy and safety has not been proven, we don’t believe it should be used.”

Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, “We have no doubt that stem cell therapies will be a major factor in combating a variety of medical conditions but it is essential that it be undertaken only after the clinical results determine that such a course of action is efficacious. Too much hype about cures for all types of diseases is diminishing the potential value of stem cells and could unduly delay future progress in stem cell treatments and research. Medical tourism is not a dirty word, if established in an ethical and professional manner.”

Cohen added, “At Proteonomix we have adopted a rigorous and cautious approach that will ensure that patients that are ultimately treated by us have confidence that the procedures will be safe, relatively low cost and offering the best chance for alleviating their specific medical condition. Our research progress has been dramatic and the procedures and intellectual property portfolio, made up of a significant number of pending patents, have resulted in Proteonomix emerging as a leader in the development of stem cell medical treatments.”

“The mission of one of our subsidiaries, Proteonomix Regenerative Translational Medicine Institute, Inc. (’PRTMI’), is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. PRTMI will undertake the creation of a global, single standard, cellular laboratory that will seek to create a seamless transition between laboratories and patient care facilities.”

Mr. Cohen concluded, “We view joint ventures with appropriate strategic partners as a key to the success of Proteonomix and, at the appropriate time, anticipate that PRTMI will engage in such discussions.”

StemCells, Inc. (Nasdaq:STEM) is engaged in the research, development, and commercialization of stem cell therapeutics and enabling technologies for use in stem cell-based research and drug discovery. StemCells cellular medicine programs target diseases of the central nervous system (CNS) and Liver.

StemCells is a world leader in the discovery and development of human neural stem cell technology. StemCells lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children.

StemCells also markets specialty cell culture products under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery, and development.

StemCells strong intellectual property position includes exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents.

StemCells scientific founders, who are also members of the Company’s Scientific Advisory Board, are recognized as world leaders in stem cell biology.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

To unsubscribe: unsubscribe@drstockpick.com

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).

Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

**************************************************************

PROTEONOMIX, INC. (Pinksheets:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, applauds the actions taken by the Costa Rican Ministry of Health to crack down on unauthorized stem cell clinics. The chief of the ministry’s research council, Dr. Ileana Herrera, stated, “If (stem cell treatment’s) efficacy and safety has not been proven, we don’t believe it should be used.”

Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, “We have no doubt that stem cell therapies will be a major factor in combating a variety of medical conditions but it is essential that it be undertaken only after the clinical results determine that such a course of action is efficacious. Too much hype about cures for all types of diseases is diminishing the potential value of stem cells and could unduly delay future progress in stem cell treatments and research. Medical tourism is not a dirty word, if established in an ethical and professional manner.”

Cohen added, “At Proteonomix we have adopted a rigorous and cautious approach that will ensure that patients that are ultimately treated by us have confidence that the procedures will be safe, relatively low cost and offering the best chance for alleviating their specific medical condition. Our research progress has been dramatic and the procedures and intellectual property portfolio, made up of a significant number of pending patents, have resulted in Proteonomix emerging as a leader in the development of stem cell medical treatments.”

“The mission of one of our subsidiaries, Proteonomix Regenerative Translational Medicine Institute, Inc. (’PRTMI’), is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. PRTMI will undertake the creation of a global, single standard, cellular laboratory that will seek to create a seamless transition between laboratories and patient care facilities.”

Mr. Cohen concluded, “We view joint ventures with appropriate strategic partners as a key to the success of Proteonomix and, at the appropriate time, anticipate that PRTMI will engage in such discussions.”

StemCells, Inc. (Nasdaq:STEM) is engaged in the research, development, and commercialization of stem cell therapeutics and enabling technologies for use in stem cell-based research and drug discovery. StemCells cellular medicine programs target diseases of the central nervous system (CNS) and Liver.

StemCells is a world leader in the discovery and development of human neural stem cell technology. StemCells lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children.

StemCells also markets specialty cell culture products under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery, and development.

StemCells strong intellectual property position includes exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents.

StemCells scientific founders, who are also members of the Company’s Scientific Advisory Board, are recognized as world leaders in stem cell biology.

International Stem Cell Corporation (OTCBB:ISCO), via its wholly-owned subsidiary, Lifeline Cell Technology® and Sristi Biosciences have entered into a distribution agreement for the Lifeline® brand of human cell culture products in India.

Lifeline specializes in development, manufacture and distribution of primary human cells and media and growth factors for optimized culturing of cells, including stem cells. These products are being requested by customers internationally, including in India, which represents one of the fastest growing markets for products of this kind.

Lifeline’s scientists have over 20 years of experience developing products for the culture of human cells. The company has made significant contributions to the creation and standardization of human cell systems used today for clinical applications and in academic, government and pharmaceutical research laboratories. The group sells over 75 standardized products directly and via its distributors in the US and abroad. It also engages in customized product development for its largest customers.

ISCO recently reported the beginning of a collaboration on its human corneal tissue, CytoCor™, with leading Indian eye hospital and research center, Sankara Nethralaya, and Letter of Intent with Insight Bioventures India (IBVI) to seek funding and establishment of development and manufacturing operations for ISCO’s research and pharmaceutical products in India (ISCO India), including the Lifeline products and CytoCor.

“The Lifeline distribution agreement with Sristi Biosciences is central to ISCO’s international expansion. Besides facilitating commercialization of the Lifeline products in India, Sristi Biosciences’ cell therapy development, regulatory and manufacturing expertise will be important as ISCO and IBVI seek to establish ISCO India with cost-efficient development and manufacturing of research and pharmaceutical products for the Indian and broader Asian markets,” says Brian Lundstrom, ISCO’s President.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

__

PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

** PWRM, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX).

These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PWRM has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals.

Lourdes R. Bosquez, MD, has a large private practice as well as 3 Medical Directorships in Psychiatry. Her current work in the last 9 years has been in dementia at: Cy Fair Medical Hospital, Tomball Texas; Methodist Hospital Willowbrook, Texas; and Directions of Recovery, a substance abuse program. She is a consultant to several large drug companies. Some of her research work includes “Diagnosing Depression in Cancer Children.” She presents papers at a many national neurological meetings. Dr. Bosquez is active in community functions and participates in training and education.

More about PWRM at www.power3medical.com

**************************************************************

STEM, StemCells Inc.

STEM is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its cellular medicine programs, STEM is developing therapeutic products targeting diseases of the central nervous system and liver.

** STEM and the Children’s Hospital of Orange County (”CHOC Children’s”) reported that they have entered into an agreement that provides CHOC Children’s with a royalty-free research license to certain of STEM’s patents. This license authorizes CHOC Children’s to proliferate, maintain and use human neural stem cells for non-commercial purposes.

STEM owns or has exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents. Many of the STEM’s patents include claims covering composition of matter and methods for the isolation, expansion, genetic manipulation, and use of neural stem and progenitor cells for both therapeutic use and non-therapeutic applications such as drug discovery and screening. STEM maintains an active licensing program for its technologies, and has several non-exclusive license agreements in place with leading pharmaceutical and research-based companies; as well as various on-going collaborations with stem cell researchers.

More about STEM at www.stemcellsinc.com.

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) . Rule 17B requires disclosure of payment for investor relations. . Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).

Dr Stock Pick HOT News & Alerts!

FREE Daily Stock Alerts From DrStockPick.com

DrStockPick.com Watch List!

My Pick for Monday May 10, 2010 is:

*******************

PWRM, Power 3 Medical Products Inc., PWRM.OB

More on PWRM

Stem cells are distinguished from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity. Second, under certain physiologic or experimental conditions, they can be induced to become tissue- or organ-specific cells with special functions. In some organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn out or damaged tissues. In other organs, however, such as the pancreas and the heart, stem cells only divide under special conditions.

Stem cell research is one of the most fascinating areas of contemporary biology, but, as with many expanding fields of scientific inquiry, research on stem cells raises scientific questions as rapidly as it generates new discoveries.

Results from a first stage trial with Parkinson’s patients provides additional promise for patients suffering from Alzheimer’s, clinical trials are expected to begin within the next several months.

If as we believe Stem Cells will be the panacea it is expected to be, the biomarkers developed by PWRM could become very valuable tools in the fight to find a cure, by providing the earliest onset of Alzheimer’s, even before the symptoms have become pronounced.

Just take a look at PWRM’s 5 day chart

PWRM’s chart speaks by itself!!

Let us remind you that recently, a joint provisional patent application entitled, “Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy” has been filed by the principals of StemTroniX and PWRM with the United States Patent and Trademark Office.

The provisional patent application discloses technologies designed to enhance the therapeutic process capabilities through the identification of the patients’ own stem cells. This patent application will be assigned by the inventors to the surviving public entity, to be named “StemTroniX,” upon the closing of the acquisition of StemTroniX by PWRM (in February 2010, PWRM entered into a definitive merger agreement to acquire StemTroniX, Inc., a stem cell biotechnology acquisition and holding company that is committed to improving the lives of individuals by using autologous adult stem cell technology to repair tissue damage in patients).

Keep a close eye on PWRM from now on!!

PWRM is trading around $0.07 cents.

There is still time to include PWRM to your watch list!!

The combination Stem Cell Biotechnology - Protein Biomarkers could be explosive for PWRM’s trading levels and you don’t want to be out of the action!!

More about PWRM at www.power3medical.com.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).